Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
brinzolamide, brimonidine tartrate
Novartis Europharm Limited
S01EC54
brinzolamide, brimonidine tartrate
Ophthalmologicals
Ocular Hypertension; Glaucoma, Open-Angle
Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
Revision: 10
Authorised
2014-07-18
25 B. PACKAGE LEAFLET 26 PACKAGE LEAFLET: INFORMATION FOR THE USER SIMBRINZA 10 MG/ML + 2 MG/ML EYE DROPS, SUSPENSION brinzolamide/brimonidine tartrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, optometrist (optician) or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, optometrist (optician) or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What SIMBRINZA is and what it is used for 2. What you need to know before you use SIMBRINZA 3. How to use SIMBRINZA 4. Possible side effects 5. How to store SIMBRINZA 6. Contents of the pack and other information 1. WHAT SIMBRINZA IS AND WHAT IT IS USED FOR SIMBRINZA contains two active substances, brinzolamide and brimonidine tartrate. Brinzolamide belongs to a group of medicines called carbonic anhydrase inhibitors and brimonidine tartrate belongs to a group of medicines called alpha-2 adrenergic receptor agonists. Both substances work together to reduce pressure within the eye. SIMBRINZA is used to lower pressure in the eyes in adult patients (aged 18 years and over) who have eye conditions known as glaucoma or ocular hypertension and whose high pressure in the eyes cannot be controlled effectively by one medicine alone. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE SIMBRINZA DO NOT USE SIMBRINZA - if you are allergic to brinzolamide or brimonidine tartrate or any of the other ingredients of this medicine (listed in section 6) - if you are allergic to sulphonamides (examples include medicines used to treat diabetes and infections and also diuretics (water tablets)) - if you are taking a monoamine oxidase (MAO) inhibitors (examples include medicines to treat dep Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT SIMBRINZA 10 mg/mL + 2 mg/mL eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1.3 mg of brimonidine. Excipient with known effect Each mL of suspension contains 0.03 mg of benzalkonium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, suspension (eye drops). White-to-off-white uniform suspension, pH 6.5 (approximately). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction(see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Use in adults, including the elderly _ The recommended dose is one drop of SIMBRINZA in the affected eye(s) two times daily. _Missed dose _ If a dose is missed, treatment should be continued with the next dose as planned. _Hepatic and/or renal impairment _ SIMBRINZA has not been studied in patients with hepatic impairment and caution is therefore recommended in this population (see section 4.4). SIMBRINZA has not been studied in patients with severe renal impairment (CrCl <30 mL/min) or in patients with hyperchloraemic acidosis. Since the brinzolamide component of SIMBRINZA and its metabolite are excreted predominantly by the kidney, SIMBRINZA is contraindicated in such patients (see section 4.3). _Paediatric population _ The safety and efficacy of SIMBRINZA in children and adolescents aged 2 to 17 years have not been established. No data are available. SIMBRINZA is contraindicated in neonates and infants aged less than 2 years in the decrease of elevated intraocular pressure (IOP) with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction because of safety concerns (see section 4.3). 3 Method of administration For ocular use. Patie Aqra d-dokument sħiħ